Our ME/CFS Research Log

Onset commonly preceded by infection in many patients, but underlying mechanism not understood; treats infection as a recognized precipitating factor, not proven etiology.

~1 in 10 people infected with EBV, Ross River virus, or Coxiella burnetii later develop an ME/CFS-like illness, especially after severe acute symptoms; SARS-CoV-2/Long COVID also a recognized trigger.

Cause unknown, but onset often temporally linked to infection or other prodromal event (also immunization, trauma, environmental exposure); flags infection as a priority research area.

Post-infective CFS-meeting fatigue developed in a minority of patients regardless of pathogen (EBV/Ross River/Coxiella); predicted by acute illness severity, not psychological factors.

13%, 7%, 4% of adolescents met CFS criteria at 6/12/24 months post-mono; most recovered, greater 12-month severity predicted 24-month persistence.

51% (95% CI 42-60%) of Long COVID patients met formal ME/CFS diagnostic criteria; high heterogeneity (I2=91%).

ME/CFS incidence 2.66/100 person-years in infected vs 0.93 in uninfected controls (HR~4.9); 4.5% of infected met post-COVID ME/CFS criteria vs 0.6% uninfected.

12 of ~17 reviewed enterovirus RT-PCR studies found evidence of enteroviral infection in a subset of patients; authors conclude prior negative studies used inadequate primer design, question remains unresolved.

~30% of ME/CFS-following-mono cases show a distinct pre-illness immune signature; baseline plus acute GI symptoms during mono predicted ~80% likelihood of severe ME/CFS.

Frames ME/CFS/Long COVID/related conditions collectively as "infection-associated chronic conditions" - treats post-infectious onset as clinically established for management purposes even though causal mechanism unproven.

Summarizes OMF-funded research on molecular/epigenetic changes hypothesized to link severe viral infection to ME/CFS onset - working hypothesis under investigation.

States ME/CFS onset "often" triggered by infectious-like illness (EBV, Ross River, Coxiella burnetii, enterovirus, herpesviruses, SARS-CoV-2).

PTLDS affects an estimated ~10% of properly-treated Lyme patients; review found PTLDS meets at least 4 of 6 major ME/CFS diagnostic criteria in most studies, with a shared 'cell danger response' mechanism being actively tested.

Lists "immune system dysfunction" alongside HPA-axis hypoactivity and autonomic dysfunction as a hypothesized maintaining factor, not an established cause.

States it's possible ME/CFS is caused by immune-system changes; shares features of autoimmune illness but tissue damage (a typical autoimmune hallmark) has not been found.

Frames infection/immunization/environmental exposure as plausible trigger; full immune-evidence chapter (Ch.5) not independently fetchable in this pass.

Impaired NK cell cytotoxicity was the most consistent immunological finding across all publications reviewed; other NK phenotype markers were inconsistent.

NK cell cytotoxicity reduced to roughly half of healthy-control levels (Hedges' g=0.96); high heterogeneity explained by assay/ratio differences, not absence of effect.

"Little or no evidence" pro-inflammatory cytokines generally raised in CFS, except TGF-beta (elevated in 5/8 studies that measured it).

Findings across studies inconclusive on whether cytokines play a definitive role; circulating cytokines not currently reliable as biomarkers.

Only 2/~51 cytokines differed between cases and controls overall, but 17 cytokines correlated with disease severity - severity-dependent signature, not a diagnostic one.

Distinct cytokine profiles differentiated short-duration (<=3yr) from long-duration illness, consistent with an early antiviral/immune-activation response not sustained over time.

~29.5% of CFS patients had elevated autoantibodies against M3/M4 muscarinic and beta-2 adrenergic receptors vs controls - a subset finding, later replicated in an independent Swedish cohort.

Autoimmune mechanisms plausibly apply to a subset of ME/CFS patients, not the condition as a whole; frames ME/CFS as heterogeneous with autoimmunity as one of several subtype mechanisms.

Summarizes OMF-funded research emphasizing immune dysregulation as one pillar of a multi-system model, alongside metabolic and vascular dysfunction.

States inflammatory cytokines (IL-6, IL-10, TNF-alpha) increase following exertion and are believed to contribute to neuroinflammation and PEM.

Summarizes primary literature (cytokines, activated lymphocytes, MAIT cell elevation in severe patients per UK ME/CFS Biobank, microglial activation) as evidence of an immune-mediated component.

CD3+ T-cell infiltration present in long COVID muscle before exercise (absent in healthy controls) and increased after an exhaustive exercise test; small atrophic fibers more abundant in long COVID and increased post-exercise in both groups (p<0.001); necrotic fibers seen in 36% of long COVID patients post-exercise but the group difference vs controls was not statistically significant (p=0.09). Authors describe a "locally disturbed immune response" - they do not use the word "autoimmune" anywhere in the paper; that framing is a reader/secondary-source inference, not the study's own conclusion.

Large, high-profile 75-investigator, 15-NIH-institute study. Found abnormal motor-cortex activity during effort tasks despite no measurable peripheral muscle fatigue (points to a CNS/effort-perception mechanism rather than muscle failure); immune profile suggesting chronic antigenic stimulation (increased naive B-cells, decreased switched-memory B-cells); notable sex differences.

Proposes that chronic innate-immune activation (via interferon-alpha) locks cells into a metabolic bypass (the itaconate shunt) that impairs the TCA cycle and ATP production. Genuine, current, credible research program (OMF-funded, published explainer material and a zebrafish model experiment) but hypothesis-stage, not a clinical trial result.

Recognizes orthostatic intolerance (including POTS and postural hypotension) as a common feature; recommends pharmacological OI treatment only under a clinician with relevant expertise.

OI is one of the core diagnostic features (with PEM, unrefreshing sleep, and either OI or cognitive impairment required); up to ~75% of adults show elevated resting HR/BP changes.

OI frequently present and helps distinguish ME/CFS from other fatiguing illness; new diagnostic criteria require cognitive impairment OR OI alongside fatigue/PEM/unrefreshing sleep.

ME/CFS patients had significantly higher resting HR (+4.14bpm), higher LF/HF ratio (sympathetic dominance), lower resting HF-HRV (vagal marker) vs controls.

POTS prevalence did not differ between CFS and non-CFS fatigued patients (adults 5.7% vs 6.9%, p=0.54); important discordant/skeptical result.

26% reduction in cerebral blood flow during tilt testing vs 7% in controls, occurring even in the subgroup with entirely normal HR/BP response.

COMPASS-31 autonomic symptom score 34.1 vs 6.8 (p<0.0001); 97% of ME/CFS participants had at least one measurable autonomic abnormality.

ME/CFS and post-COVID patients showed similar HRV and baroreflex impairment, suggesting overlapping autonomic pathophysiology with post-viral illness.

Argues clinical pathways should recognize the full spectrum of OI, not just strict POTS heart-rate thresholds; tolerated upright activity hours correlate with symptom burden.

States both POTS and non-tachycardic dysautonomia are "major pathophysiologic mechanisms" - stronger causal framing than the peer-reviewed base currently supports.

Does not single out mitochondrial/energy metabolism dysfunction as a defined mechanism; names only broad categories (genetic, infection, immune, HPA-axis, autonomic).

Lists "how the body uses energy" as one of several areas under active research, alongside infection, immune response, inflammation, toxins, genetics.

Made PEM a required diagnostic criterion (renaming the illness SEID) based on exercise-physiology evidence; specific mitochondrial-mechanism language in the report not independently confirmed.

No disease-causing mitochondrial DNA variants found; inconsistent ATP/OXPHOS results across studies; some evidence of disrupted TCA cycle activity and reduced CoQ10 in two studies.

All four measured exertion parameters declined from day1 to day2 of repeated CPET in ME/CFS patients while controls improved - one of the most consistently replicated objective findings in the field.

6/9 studies of mitochondria-targeting nutraceuticals (CoQ10, NADH, carnitine) reported fatigue improvement, but authors concluded evidence is insufficient given small samples and short durations.

~15% Complex V (ATP synthase) efficiency deficit, compensated by upregulated respiratory complexes; steady-state ATP and mtDNA copy number normal.

Rules out autoimmune attack on mitochondria as the mechanism - only 1/161 ME/CFS patients tested positive for anti-PDC antibodies vs 15/15 in the PBC comparison group.

Patients showed elevated lactate at any given power output, and lactate accumulation worsened on repeat testing 24h later while controls improved.

Patients hit anaerobic threshold at much lower workloads and deteriorated on repeat testing, yet direct biochemical mitochondrial ATP-synthesis assay was normal - argues the deficit is secondary, not a primary mitochondrial defect.

States there is "growing evidence" mitochondria don't function correctly in ME/CFS; cites B-cell bioenergetics work and a "nitrogen hypothesis."

Summarizes NIH WASF3-protein finding, a BHC RNA-seq study (40 vs 31) finding mitochondrial gene variants in most patients, and a 2024 case report of rare mtDNA mutations.

Directly tests the deconditioning hypothesis using an actual experimental deconditioning model (60 days of controlled bed rest) instead of just untrained controls. Patient muscle (fewer capillaries, more glycolytic fiber type) differed qualitatively from bed-rest-induced muscle changes (which showed classic disuse atrophy) despite similar reductions in aerobic capacity - "physical inactivity alone does not explain the lower exercise capacity in long COVID and ME/CFS."

OP describes lifelong (childhood-onset) symptoms, worsening after HRT and COVID, diagnosed via organic-acid/amino-acid/acylcarnitine panel as 'mitochondrial dysfunction with wide cofactor deficiency,' treated with ALA/CoQ10/B-vitamin/cofactor stack with strong short-term (2-week) improvement. A recurring 'supplement poop-out' pattern (dramatic improvement then fade) independently corroborated by 4 other commenters using different supplement classes (methylated B vitamins, SAMe, NAC, sodium butyrate, ubiquinone, ALA, berberine) - consistent with the pattern already logged for aripiprazole (S256), suggesting this may be a general ME/CFS supplement-response phenomenon rather than drug-specific.

Management-oriented, not etiological - does not substantively engage with neuroinflammation, glial activation, or central sensitization as an underlying mechanism.

Lists systemic immune dysfunction (NK/T-cell function, inflammatory cytokines) as a candidate cause but does not specifically discuss CNS-localized neuroinflammation or glial activation.

Does not discuss neuroinflammation, glial/microglial activation, or CNS sensitization mechanisms at all - focuses on diagnostic criteria and disease burden, silent on this specific mechanism.

Strongest, most consistent meta-analytic signal was hypoactivity in insular and thalamic regions - hub regions for cognition/emotion/pain processing, offering a plausible substrate for brain fog and pain amplification.

Landmark finding: microglial activation marker was 45-199% higher in ME/CFS patients across cingulate cortex, hippocampus, amygdala, thalamus, midbrain, and pons, correlating with pain and cognitive symptom severity. Very small N, unreplicated at scale.

Found no significant difference in microglial activation marker between either patient group and healthy controls - directly contradicts Nakatomi 2014, a key disconfirming data point. Same small-N limitation as the study it tested.

Distinct, markedly disturbed CSF immune signature in ME/CFS - elevated CCL11/eotaxin and disrupted IL-1 signaling network, interpreted as CNS immune activation with a Th2/allergic skew, distinct from MS comparator group.

Ventricular lactate (marker of localized oxidative stress/glial dysfunction) significantly elevated in CFS, fibromyalgia, and CFS+FM groups vs controls, but did not differentiate patient groups from each other - shared CNS oxidative-stress mechanism, not CFS-specific.

States there is "now a solid body of evidence showing the brain is inflamed in ME/CFS patients" and promotes brain donation since postmortem tissue is currently the only way to directly examine neuroinflammatory pathology.

Frames low-grade CNS neuroinflammation as a core working hypothesis; funding a large-scale study combining CSF collection, intracranial pressure measurement, and diffusion-MRI microglial imaging to address the small-N replication problem.

Announces a formal partnership targeting neuroinflammation/microglial activation across ME/CFS, Long COVID, and other infection-associated chronic conditions - signals where major advocacy funding is being directed, reports no new data itself.

Lists 9am cortisol as an optional test to exclude adrenal insufficiency (differential diagnosis, not diagnostic marker); companion evidence review recognizes HPA hypoactivity as a plausible maintaining factor.

Notes some patients show HPA axis dysregulation, specifically flattened diurnal cortisol profiles, while cortisol levels typically remain within normal range - subtle dysregulation, not frank adrenal insufficiency.

HPA/cortisol findings are not a headline conclusion - diagnosis centers on PEM, unrefreshing sleep, cognitive impairment, orthostatic intolerance; HPA abnormalities appear as one of many candidate findings in broader evidence-review chapters.

Synthesizes basal hypocortisolism, enhanced negative feedback, and attenuated diurnal cortisol variation in CFS - qualitatively distinct from the hypercortisolism of major depression. Notes marked inter-study variability.

Most recent and rigorous quantitative synthesis: confirms reduced bioactive (free/active) cortisol availability and exaggerated HPA negative-feedback sensitivity vs controls, formalizing the older narrative-review consensus with meta-analytic methods.

Foundational study: low 24-hour urinary free cortisol and reduced evening plasma cortisol, concluding the pattern was "most compatible with mild central adrenal insufficiency."

Lower post-dexamethasone salivary cortisol in CFS patients (enhanced negative-feedback sensitivity) - but only clearly present in the subgroup without early-life stress history, suggesting trauma history is an important moderator/confound.

Hydrocortisone 5-10mg/day for 1 month produced significantly larger fatigue improvement than placebo (28% reached normal scores vs 9%); small sample, short duration, authors called for longer follow-up before clinical conclusions.

Higher-dose regimen produced some symptom improvement over placebo, but caused clinically significant adrenal suppression - authors explicitly concluded this "precludes its practical use" despite the symptomatic signal.

Brief acknowledgment that PEM is accompanied by "aberrancies among both autonomic functioning and HPA axis functioning" - a minor theme in BHC's public material, not a centerpiece.

Does not address gut microbiome/dysbiosis as a causal mechanism; mentions GI conditions (IBS, gastroparesis) only once as a possible comorbidity to screen for.

Gut microbiome/dysbiosis is not mentioned at all as a causal category; lists infections, energy metabolism, immune response, genetics/environment instead.

No mention of gut microbiome, dysbiosis, or intestinal permeability anywhere in the report - the gut-microbiome hypothesis predates/postdates this report's scope entirely.

Only 3/7 included studies showed statistically significant microbiome differences, results inconsistent across studies; concluded insufficient evidence for enteric dysbiosis playing a significant role in ME/CFS.

Reduced bacterial diversity, lower anti-inflammatory Firmicutes, elevated blood markers of microbial translocation (LPS, LBP, sCD14); authors explicitly state they cannot determine cause vs consequence.

Detected taxa shifts between ME/CFS patients and controls, but patterns differed between the two national cohorts - an early signal of the cross-study inconsistency later flagged by the 2018 systematic review.

Short-duration ME/CFS showed more pronounced dysbiosis (depleted butyrate-producers) than long-duration disease, which showed more severe metabolic/phenotypic abnormality instead - suggesting dysbiosis matters more early in illness. Largest, most rigorous study in this category.

Significantly elevated gut permeability/bacterial translocation markers (zonulin-1, LPS, sCD14) vs controls; zonulin-1 correlated with autonomic dysfunction severity.

Single patient treated with antioxidants/leaky-gut diet/IVIG showed normalized endotoxin translocation alongside symptom remission - early proof-of-concept, not generalizable.

Lactobacillus casei significantly reduced anxiety scores vs placebo but had no effect on depression; measured mood outcomes, not fatigue or GI symptoms directly.

First RCT testing donor FMT vs autologous FMT/placebo in ME/CFS; protocol only, no efficacy data available yet - the most direct test of the causal hypothesis, still pending.

Frames the Xiong et al. multi-omics findings as foundational for future clinical trials; highlights reduced butyrate-producing bacteria as candidate biomarkers.

Names genetic predisposition and female gender as predisposing factors within a model of immune-system stressor triggering illness in a genetically predisposed individual; one factor among several, no specific genes cited.

States twin/family studies suggest genes and environment both play a role (higher concordance in identical vs fraternal twins) but scientists have not yet found the exact genes responsible.

Explicitly states the committee was not asked to investigate etiology/pathogenesis; genetics is essentially absent from this report's scope - a useful negative data point showing how recent the genetic evidence base is.

Most prior candidate-gene associations failed to replicate in the larger UK Biobank CFS cohort; concludes ME/CFS likely involves many genetic contributions of small individual effect, motivating a well-powered GWAS (i.e. DecodeME).

Significant excess CFS relative risk in 1st- (RR 2.70), 2nd- (RR 2.34), and 3rd-degree relatives; elevated risk persisting into distant relatives who share little common environment supports a genetic, not purely environmental, contribution.

Monozygotic twin fatigue correlation (0.49) more than double dizygotic (0.16), yielding ~48% genetic variance estimate; but authors concluded immune-activation fatigue specifically was more driven by current environmental exposures than genetics alone.

First adequately-powered GWAS: 8 genome-wide-significant loci found (near BTN2A2, OLFM4, RABGAP1L, linked to immune/infection response, plus a chronic pain locus); common-variant heritability modest (~10%), implying environment/rarer variants likely dominate.

17296 differentially methylated CpG sites across 6368 genes found, predominantly hypomethylation concentrated in immune-signaling pathways - validated in a second cohort despite small discovery N.

Summarizes T-cell methylation research finding altered methylation at HLA-DQB1 and SLC25A24 genes; could not independently trace to a specific peer-reviewed citation in this research pass.

Does not mention small fiber neuropathy, skin biopsy, or intraepidermal nerve fiber density anywhere; defers to NICE's separate neuropathic pain guideline (CG173) for pain management generally.

No reference found to small fiber neuropathy, skin biopsy, or IENFD in the autonomic dysfunction evidence chapter - consistent with timing, since the first dedicated ME/CFS SFN skin-biopsy study wasn't published until 2021.

CDC's own clinical overview doesn't name SFN as a mechanism, but CDC's stakeholder call series has hosted outside researchers presenting SFN as a candidate mechanism for exercise intolerance - CDC-hosted, not CDC-endorsed.

First dedicated ME/CFS SFN assessment via skin biopsy: 31% of ME/CFS patients met SFN criteria (p<.0001 vs controls). Proposed mechanism: SFN-driven neurovascular dysregulation impairing venous return during exercise, linking SFN to PEM.

34% of ME/CFS patients had pathological electrochemical skin conductance in palms (12% in soles), indicating small-fiber sudomotor dysfunction; heat-evoked potential latencies significantly prolonged, consistent with unmyelinated fiber damage.

Using multimodal testing (Sudoscan, evoked potentials, corneal confocal microscopy), fiber tortuosity (not density) was the best discriminator between patients and controls (AUC=0.72) - suggests standard density-based biopsy may under-detect SFN in this population.

Pooled somatic small-fiber impairment prevalence 49% in fibromyalgia. Closest analog to an ME/CFS-specific meta-analysis (none exists), frequently cited due to symptom/mechanism overlap, but should be read as adjacent, not direct, evidence.

Summarizes the case for SFN as a plausible contributor to ME/CFS pain/autonomic symptoms, citing 30-80%+ prevalence range across small studies and candidate mechanisms (autoimmunity, bradykinin, mast cell activation).

Plain-language summary of the Joseph et al. 2021 findings, framing SFN-driven microvascular shunting as a candidate explanation for exercise intolerance and PEM.

No mention of mast cell activation/MCAS found in NG206 itself; a separate ME Association document says MCAS "should be considered" for severe GI symptoms, but that's advocacy-body supplementary guidance, not NICE language.

Core 2015 diagnostic criteria make no reference to mast cells or MCAS; full immune-dysfunction chapters not independently confirmed to address it either way.

Establishes the field's formal MCAS diagnostic criteria: mediator symptoms across >=2 organ systems, an event-related tryptase rise above individual baseline, and response to anti-mediator therapy - a stricter bar than most ME/CFS-MCAS studies actually apply.

16.7% of survey cohort and 25.3% of clinical cohort met criteria for clinically relevant mast cell activation; MCAS-positive patients had significantly higher orthostatic intolerance rates (89% vs 72%) and significantly better response to mast-cell-targeted treatment (p<0.0001).

High-dose oral cromolyn sodium (1600-2400mg/day) improved symptoms in all 5 ME/CFS+MCAS patients who hadn't responded to standard dosing - reduced flushing, less PEM, better orthostatic tolerance; wellness scores roughly tripled in two patients.

Significant increase in mast cell progenitor populations in peripheral blood vs controls, with elevated activation markers in severe cases - biological plausibility, not a clinical prevalence or diagnostic finding.

Proposes mast-cell mediators and ME/CFS-associated muscle mediators converge on shared vascular effects via dysfunctional beta2-adrenergic signaling - a candidate mechanistic bridge between MCAS, POTS and ME/CFS, explicitly framed as an untested hypothesis.

States MCAS is seen frequently in their ME/CFS, Long COVID and hypermobility populations, but explicitly acknowledges "there currently is no robust research to confirm a link between ME/CFS and MCAS" - an honest hedge from a leading clinical center.

Confirms extensive symptom overlap and describes an "Overlapping Illness Alliance" spanning ME/CFS, POTS and MCAS as a coordinated cross-charity advocacy effort - reflects patient-community interest, not new clinical evidence.

~7-8 commenters describe migraine-pattern symptoms masquerading as PEM, later attributed to MCAS/histamine intolerance. Valuable differential-diagnosis nuance: several long-time community members explicitly and correctly pushed back on OP's initial 'I never had ME/CFS' conclusion, pointing out MCAS is something 'all people with ME are encouraged to rule in or out' (not either/or) and that a few weeks of improvement is too short a window to rule out comorbid ME/CFS. Concrete real-world dosing detail: high-dose H1+H2 antihistamine protocol (fexofenadine up to 360mg/day, famotidine 40-80mg/day vs. normal allergy doses), hydroxyzine reported to abort migraine specifically.

Recommends personalized sleep management (regular habits, rest-period pacing, gradual pattern changes) rather than treatment for a defined sleep pathology; only refers to sleep specialist if these strategies fail.

Stepped approach (sleep hygiene to OTC aids to prescription meds to specialist referral/sleep study); explicitly notes patients "can still have unrefreshing sleep even though they achieve required hours of sleep."

States "standard sleep studies are not substantially abnormal" in most patients; unrefreshing sleep was made a core diagnostic criterion because the subjective complaint is near-universal, not because polysomnography reliably documents a distinct abnormality.

No consistent group differences in total sleep time or onset latency; slow-wave sleep and apnea-hypopnea findings inconsistent between studies. Most consistent finding: elevated microarousal index across all 5 studies that measured it.

Adult ME/CFS patients show longer sleep onset latency, more wake-after-sleep-onset, reduced sleep efficiency vs controls - but these objective differences don't track with or explain the magnitude of subjective unrefreshing-sleep complaints (an "objective-subjective disconnect").

Alpha-delta sleep intrusion found in ~25% of patients but not significantly correlated with CFS, fibromyalgia, or depression specifically; ~a third had a concurrent primary sleep disorder. Not a specific/reliable CFS marker.

40.3% of those PSG'd had obstructive sleep apnea, 41.0% restless legs syndrome, 69.3% had at least one treatable sleep disorder - suggesting a substantial fraction of "ME/CFS" sleep complaints in referral populations are a distinct, treatable comorbid disorder.

Both treatment and placebo groups improved on sleep quality (large placebo effect); melatonin+zinc showed a modest edge on sleep latency. Used only subjective PSQI outcomes, no objective sleep measures.

Practical guide covering self-help strategies and drug options; frames sleep problems as heterogeneous (insomnia, hypersomnia, reversed cycle, non-restorative sleep) requiring individualized management.

OP + ~35 comments, overwhelmingly reinforcement: OSA comorbidity (4 independent reports, corroborates existing S132 ~40% finding) and deep-sleep-quality-over-quantity disconnect (corroborates existing S130 meta-analysis). New nuance: bidirectional causality (overexertion disrupts sleep first, which then snowballs - a feedback loop, not one-directional) and a patient-reported clinician hypothesis linking the glymphatic-clearance study (S257) to a 'worse with more sleep if woken mid-deep-sleep' pattern - speculation on a pilot finding, not new data.

Withdrew GET and downgraded CBT to supportive-only, explicitly rejecting the model where illness-perpetuating beliefs are the maintaining cause; defended this reversal in 2023 against pushback from PACE-aligned researchers.

Concluded ME/CFS is "a serious, chronic, complex systemic disease" and explicitly "not a psychological entity"; noted a 1970 psychogenic reinterpretation of a historical outbreak was later "strongly refuted."

States plainly: "ME/CFS is a biological illness, not a psychologic disorder. Patients... are neither malingering nor seeking secondary gain," citing documented immune/endocrine/nervous-system abnormalities.

Elevated rates of pre-existing depression/anxiety medication before CFS diagnosis - but claims-database study using medication proxies, cannot distinguish misdiagnosed prodromal ME/CFS symptoms from true independent pre-existing psychiatric illness.

In participants free of prior fatigue at baseline, pre-existing psychiatric disorder did NOT predict later CFS onset - the key direct test of the psychogenic-primary-cause hypothesis, and it comes back negative.

Fatigued twins more depressed/anxious than non-fatigued co-twins regardless of zygosity - suggests shared environment/illness burden drives the mood association, not shared genes. Used a broader fatigue phenotype, not strict ME/CFS criteria.

Argues the CBT/GET model isn't empirically supported and conflicts with documented immune/neurological/metabolic abnormalities; cites PACE's re-analyzed recovery rate near 7% vs originally reported 22%.

Reviews organic abnormalities contradicting psychosomatic/deconditioning models and documents concrete patient harm from psychosomatic misattribution; cites ~90% of ME/CFS patients report being told symptoms were psychosomatic before diagnosis.

Documents NICE's rebuttal to researchers who called the 2021 guideline reversal a "controversial U-turn," and frames the historical CBT/GET consensus's origins - useful as documentation of the dispute, not independent evidence.

Recommends individualized energy management (pacing) as core self-management; explicitly advises against fixed incremental structured exercise (classic GET) that ignores PEM. Deliberate 2021 repositioning from 2007 GET/CBT-favoring guidance.

No approved treatment exists, but pacing/activity management (staying within an individually-determined energy envelope) is the primary recommended strategy to minimize PEM.

Established PEM as the cardinal diagnostic feature and endorsed activity/energy management as a central management principle, warning overexertion can cause prolonged relapse. Underpinned NICE's later 2021 pivot.

12/17 studies showed improvement on at least one outcome, but survey data showed pacing worsened symptoms in ~14% of respondents vs improved in ~44%; literature judged poor-to-fair quality.

Small positive effect on physical function (SMD ~0.15); evidence insufficient to confirm robust effects on pain or overall function.

Activity pacing significantly reduced fatigue (Hedges' g~-0.52) and psychological distress, improved physical function vs usual care - most methodologically positive meta-analysis found.

Activity Pacing Self-Management produced significantly greater satisfaction with daily activity (42% clinically relevant improvement vs 0%) and reduced fatigue vs relaxation therapy.

Established the "energy envelope" construct empirically - energy quotient correlated with fatigue severity, disability, depression, and quality of life.

Patients who stayed within their energy envelope at baseline showed significantly greater improvement in physical functioning and fatigue at 1-year follow-up than those who exceeded it.

Both PT and GET improved outcomes short-term; GET showed larger short-term gains, but at 2.5-year follow-up pacing's improvements were maintained while GET's were not.

~45% of respondents reported improvement after a pacing approach vs ~10% with GET/CBT-based approaches; directly cited in evidence submitted to NICE's 2021 guideline revision.

Operationalizes pacing clinically - target activity should avoid inducing PEM within 24-48 hours, with return to baseline by the next morning; emphasizes cognitive/emotional pacing alongside physical.

Median 5% full recovery rate (range 0-31%) and 39.5% median improvement across 14 studies, largely reflecting untreated/naturalistic course. Useful anchor figure for 'how rare is spontaneous/treated recovery' discussions.

Clinician-side (not patient-side) discussion thread. Multiple MDs/PAs independently corroborate existing verdicts: pacing as first-line treatment and NASA Lean Test for orthostatic intolerance (matches existing Pacing category and S097); screening for PEM before prescribing exercise (corroborates GET Ruled Out verdict); OSA under-diagnosis in suspected ME/CFS (corroborates existing Sleep architecture note, S132); hEDS-POTS-MCAS clustering and management (corroborates MCAS and Autonomic dysfunction categories).

Largest thread in the sweep (60+ comments). Dominant theme (10+ independent commenters) is pacing/energy-envelope management - strong reinforcement of the existing Promising verdict. Second theme: 3 independent accounts of dramatic improvement after removing a major chronic stressor (incl. leaving an abusive relationship), consistent with the existing HPA axis stress-modulation model. Single-case chiropractic (Gonstead method) improvement reported, confounded by concurrent LDN use.

States that any therapy based on fixed incremental increases in activity/exercise (classic GET) should NOT be offered; reversed the 2007 recommendation after re-grading trial evidence as low/very-low certainty and weighing extensive patient-harm evidence.

Quietly removed GET (and CBT) from treatment pages in July 2017; current guidance states people with ME/CFS do not tolerate vigorous aerobic exercise and poorly designed exercise plans can cause serious deterioration.

Established PEM as a required diagnostic feature and affirmed ME/CFS as physiological, not psychiatric - undercutting the deconditioning/exercise-avoidance theory GET was built on.

Concludes exercise therapy probably reduces fatigue vs usual care, harms evidence uncertain - but this review is under open dispute within Cochrane itself for being outdated and republished unchanged despite an advisory group recommending a "do not use for clinical decisions" notice.

The trial that anchored the 2007 NICE recommendation - reported CBT/GET produced significant fatigue/function improvement vs pacing or specialist care alone, but see Wilshire 2018 reanalysis for why this is now considered unreliable.

Reanalyzing PACE per its own pre-registered protocol thresholds, "recovery" rates for GET/CBT fell from published 60-61% to just 20-21%, and improvement differences vs controls were not statistically reliable.

A lighter-touch, self-help version of GET produced modestly lower fatigue and higher self-reported function vs specialist care alone at 12 weeks, with no excess serious adverse reactions reported - cited by GET proponents as evidence it can be delivered safely.

Argues GET/CBT trials relied on subjective self-report in unblinded designs with no matching objective improvement (fitness, employment), and that NICE's 2021 evidence downgrade was methodologically justified independent of the harms evidence.

Found GET/CBT trials of the era (including PACE) systematically under-reported adverse events - not using validated harms instruments, not counting relapse as an adverse event, excluding severely-affected patients likely to react badly.

74% of respondents who had tried GET reported it made symptoms worse (vs much lower worsening rates for pacing, ~20% for CBT) - a key piece of evidence patient groups presented to NICE during the NG206 review.

Documents objective, biopsy-confirmed muscle tissue damage and immune-cell infiltration following a maximal exercise test in a PEM population - empirical support for guideline advice (NICE/CDC) to avoid activities that trigger PEM rather than a fixed, incrementally-increasing exercise program.

Challenges S240/S241's causal interpretation on three grounds: (1) the necrosis/regeneration timeline described is biologically implausible within the ~1 day between exercise and biopsy; (2) long COVID patients averaged 30-40% fewer daily steps than controls with no fitness-matched comparator group, a deconditioning confound; (3) no correlation found between histology abnormalities and patient-reported myalgia/exercise intolerance. Authors are from a mitochondrial-disease/neuromuscular exercise-therapy research group (Radboud UMC).

Rebuts the deconditioning explanation: state their findings are not explained by bed rest/inactivity alone, that PEM is a distinct and poorly understood symptom not analogous to general deconditioning, and reaffirm guideline advice to avoid PEM-triggering activity rather than push through it.

States CBT "is not a cure for ME/CFS and should not be offered as such"; repositions it as support for coping/quality of life, not treatment of the underlying disease.

Removed CBT (and GET) as recommended primary treatments in 2017 citing insufficient evidence; current guidance frames CBT only as an optional adjunct for coping/pacing support or comorbid anxiety/depression.

Concluded ME/CFS is a medical, not psychiatric, illness with biological pathophysiology - removing the "false illness belief" theoretical basis that had justified CBT-as-cure.

Found CBT more effective than usual care/waitlist for reducing fatigue post-treatment (~40% clinically improved vs ~26%), but relied on subjective outcomes and mostly unblinded trials - flagged by the review's own authors.

As published, reported CBT/GET produced greater improvement than pacing or specialist care alone; companion 2013 paper claimed ~22% recovery with CBT/GET vs ~7% with usual care - the figure central to the later controversy.

Using the pre-registered protocol thresholds (via FOI request) rather than relaxed post-hoc ones, CBT/GET recovery rates fell to single digits and lost statistical significance vs controls; objective improvement (fitness, employment) was largely absent.

Found effect sizes below the review's own pre-specified clinical-relevance threshold, no objective improvement, and ~20% of patients reporting deterioration; recommended downgrading CBT to adjunct coping support only.

CBT reduced fatigue severity and functional impairment across subgroups including patients with PEM; effects somewhat larger in younger, less-impaired patients. Outcomes subjective/self-reported throughout.

Found small-to-moderate reductions in fatigue, fatigue-related impairment, depression and anxiety with acceptable adherence, but effects rested largely on subjective self-report outcomes.

Majority of respondents who had CBT or GET since 2007 reported no improvement or deterioration; results submitted to and cited by NICE's 2021 guideline review committee.

NG206's formal recommendations do not include LDN; the committee explicitly considered it and declined to recommend it, citing the absence of well-conducted placebo-controlled trials.

73.9% reported a positive response to LDN (3.0-4.5mg/day), most commonly in vigilance/alertness, physical performance, cognitive function; 18.3% no response. Retrospective, uncontrolled, no placebo arm.

LDN associated with restoration of TRPM3 ion channel function in NK cells to near-healthy-control levels - biological plausibility only, does not measure clinical symptom outcomes.

Significant pain reduction and increased pressure pain threshold vs placebo in fibromyalgia, no QoL/symptom-severity difference, no excess serious adverse events. Evidence borrowed from an adjacent condition, not ME/CFS itself.

Concludes LDN appears safe/efficacious for fibromyalgia pain with no severe adverse events, but authors caution well-designed large-scale studies are still needed.

Statistically significant improvements in fatigue (g=-0.74), brain fog, sleep, pain/functioning - but no RCTs exist for this indication, pre-post design without controls, authors rate overall certainty as low.

Recommends LDN (0.5-6mg/day) as low-risk/low-cost for ME/CFS, Long COVID, comorbid fibromyalgia/MCAS, citing anti-neuroinflammatory mechanism; flags vivid dreams/sleep disruption as main tolerability issue.

LDN ranked the single most-reported-effective treatment among ME/CFS patients in this survey - 60% rated it moderate-to-much-better. Unblinded self-report, strong potential for selection/placebo bias.

Reviewed valganciclovir and IV acyclovir RCTs, rated evidence low/very-low quality; IV acyclovir showed harms (mood effects, reversible renal failure) with no clear benefit. Concluded antivirals should NOT be used to treat/cure ME/CFS.

No CDC page found taking an explicit position specifically on antivirals; general guidance states no pharmacologic treatment has been proven effective in large replicated RCTs.

No significant difference between acyclovir and placebo; apparent improvement attributed to spontaneous remission/placebo effect. General population, not antibody-selected subgroup.

Significant improvement vs placebo on mental fatigue subscore, Fatigue Severity Scale, cognitive function in this antibody-positive subgroup; overall total score difference not significant. Called for larger confirmatory trials that were never completed.

Reported improvement in energy index and left ventricular function in a narrowly defined EBV-IgM-positive subgroup with abnormal Holter findings; design complicated by add-on drugs for non-responders, later follow-up not placebo-controlled.

Long-term subset-directed valacyclovir/valganciclovir associated with improvement on the clinic's own Energy Index in this open-label, uncontrolled cohort - largest sample in the category but lowest rigor (same investigator group as the RCTs above).

Concludes antivirals show "limited efficacy over a broad demographic," with positive trials confined to narrowly antibody-selected subgroups, frequently limited by small size and lack of replication. Not a formal systematic review.

In enterovirus-confirmed ME/CFS (distinct subgroup from EBV/HHV-6 studies), 75% responded to remdesivir and 52% to Paxlovid with short-lived improvement, but all relapsed within days to months. Authors state a placebo-controlled RCT is needed.

Aggregates real-world patient reports on valacyclovir/valganciclovir - mixed, some report meaningful improvement, others report significant worsening.

Lists candidate antivirals discussed in the ME/CFS community; own evidence sections explicitly stub/incomplete, cites only studies already found above.

Not enough evidence to support routinely taking vitamin/mineral supplements as a cure or symptom-management; flags vitamin D risk in housebound/bedbound patients specifically; recommends dietetic referral only for malnutrition risk.

Frames supplements as one option to discuss with a provider, but warns many treatments marketed as ME/CFS "cures" are unproven, costly, and potentially dangerous; does not endorse any specific supplement.

Insufficient evidence to recommend nutritional supplements OR elimination/modified diets for symptom relief - small trial numbers, short duration, inconsistent outcome measures.

CoQ10+selenium, CoQ10+NADH, L-carnitine variants, and guanidinoacetic acid showed statistically significant fatigue reduction; standard multivitamin/mineral and NADH alone showed no/weak benefit. Overall high risk of bias.

200mg CoQ10 + 20mg NADH daily for 12 weeks produced significant reduction in cognitive fatigue and overall fatigue score, and improved quality-of-life scores vs placebo. Largest, best-designed single RCT in this space.

Six weekly IM magnesium sulfate injections improved energy, pain, and emotional state in 12/15 vs 3/17 on placebo; CFS patients also had lower baseline red-cell magnesium. Old, small, not replicated at scale.

Significant improvement across all five VAS symptom categories and global assessment - but open-label/unblinded, no placebo arm, high risk of placebo effect. Not independently replicated in a blinded trial.

3g/day oral L-carnitine for 2 months produced significant improvement in CFS clinical status measures, outperforming amantadine in the same trial. No placebo arm, nearly 30 years old.

2000mg/day oxaloacetate for 3 months produced 27% average fatigue reduction vs 10% (non-significant) in controls; ~40% of treated patients showed >25% improvement. Not on original supplement list, adjacent mitochondrial nutraceutical.

Hydroxocobalamin (B12) nasal drops, 5000mcg twice weekly for 3 months, produced favorable response in two-thirds of patients, with a noted dose-response relationship. Open-label, no placebo, self-selected responder analysis.

Real-world dosing data: CoQ10 >200mg/day showed 14% moderate/much-better response vs 6-8% at lower doses; Mitoquinol (CoQ10 derivative) had the strongest response rate (22%); D-ribose alone underperformed (~10%).

Oxaloacetate 2000mg/day reduced fatigue >25% from baseline vs ~10% (non-significant) in placebo over 90 days, p=0.0039. Published in Frontiers in Neurology.

Dose-response signal for oxaloacetate: fatigue reduction scaled with dose (500mg BID to 1000mg TID); long-COVID subgroup saw up to 46.8% fatigue reduction at 6 weeks.

Standardized Rhodiola extract (400mg/day, 8 weeks) produced statistically significant reductions in physical/mental fatigue and functional impairment, visible within the first week, in patients with prolonged/chronic fatigue.

Found decreased plasmalogens and phosphatidylcholine/sphingomyelin levels consistent with disrupted CDP-choline metabolism in ME/CFS patients - a mechanistic/biomarker finding, not a citicoline intervention trial. Gives a genuine mechanistic rationale for why citicoline supplementation might plausibly help brain fog, but no CFS-specific citicoline RCT exists.

OP + ~90 comments, trial-and-error supplement account. Reinforces existing CoQ10/magnesium/oxaloacetate/LDN entries. New: Rhodiola (S277), citicoline/CDP-choline (S278) mechanistic lead, sub-1mg LDN titration pattern for hypersensitive patients, ashwagandha autoimmune-flare caution (verified - contraindicated in lupus/RA/Hashimoto's/MS/T1D per multiple clinical sources, relevant given ME/CFS's autoimmune-antibody subset).

Recognizes OI/POTS as a common comorbidity but gives almost no drug-specific guidance; recommends OI medication only be prescribed/overseen by a clinician with relevant expertise, with referral to secondary care if severe/worsening.

Recommends a stepped approach: non-pharmacological measures first (heat/prolonged-standing avoidance, postural counter-maneuvers, compression, increased salt/fluids), escalating to prescription medication only if those fail, generally with specialist involvement.

Recommends stepped POTS care: fluids ~2-3L/day and sodium 4000-4800mg/day plus compression/exercise first-line; pharmacological escalation (beta-blockers, midodrine, fludrocortisone, pyridostigmine) depends on presumed POTS subtype.

Compression garments, physical training, salt supplementation are the best-supported non-pharmacological first-line measures; beta-blockers and ivabradine had the most consistent RCT support among drugs; authors flag evidence overall as still scarce.

Beta-blockers (mainly metoprolol) produced significantly higher treatment efficacy than controls (79.5% vs 57.3%), with only mild non-serious adverse events (4.0%).

Fludrocortisone monotherapy was no more effective than placebo for CFS symptoms in patients with comorbid neurally mediated hypotension - a clear negative finding despite the drug's common use in general POTS guidelines.

Knee-high compression stockings (20-25mmHg) significantly attenuated the drop in cardiac output (15% vs 27%) and cerebral blood flow (14% vs 25%) during tilt testing.

A single 60mg dose of oral pyridostigmine significantly increased peak exercise oxygen uptake via improved cardiac output vs placebo, supporting a cholinergic/preload-augmenting mechanism.

Recommends the NASA 10-minute Lean Test for OI screening in all ME/CFS patients; practical management mirrors CDC/HRS guidance, stresses OI severity (not just POTS diagnosis) should drive treatment intensity.

Synthesizes patient-reported pyridostigmine use for PEM/exercise intolerance specifically (not just BP symptoms); community-cited titration ceiling ~180mg/day divided, with cholinergic crisis flagged as a known but uncommon risk.

Recommends personalised sleep management advice (explaining disturbance patterns, gradual regular habits balanced against daytime rest), but the committee explicitly acknowledged a lack of direct evidence for sleep interventions in ME/CFS specifically.

Recommends a stepped approach - sleep hygiene first, then OTC aids, then lowest-dose/shortest-duration prescription medication if unrefreshing sleep persists; states there is no approved ME/CFS treatment.

GET shows inconsistent sleep improvement across studies; CBT evidence for sleep improvement is limited (only 1 of 2 evaluations positive); no study has tested adding dedicated sleep components to these therapies.

Melatonin+zinc for 16 weeks significantly reduced physical fatigue and improved QoL vs placebo, but sleep quality improved in both arms and benefits regressed 4 weeks after stopping - not a durable, sleep-specific effect.

Higher arousal index on diagnostic polysomnography predicted symptomatic improvement among CFS+OSA patients trying home CPAP; roughly half of CFS patients studied had OSA.

Trazodone markedly improved sleep quality/duration/efficiency over 12 weeks, but 21.2% developed tachycardia - well above typical rates, a caution given ME/CFS's overlapping dysautonomia. Fibromyalgia population, not ME/CFS.

Only 1 of 12 mind-body intervention studies measured sleep as an outcome (a Baduanjin Qigong RCT, which found significant sleep quality/latency/duration improvement vs waitlist); review flags sleep measurement as a major gap in ME/CFS trials generally.

Describes sleep disturbance subtypes (early hypersomnia, insomnia, restless legs) and recommends self-help strategies plus short-acting hypnotics or low-dose amitriptyline when needed, with melatonin for severe circadian disturbance.

Does not mention antihistamines, mast cell stabilizers, cromolyn, ketotifen, or MCAS anywhere in its symptom-management recommendations, confirmed via a peer-reviewed guideline summary covering all symptom-management sections.

States MCAS "has been reported" in ME/CFS as an associated immune finding, but mentions antihistamines only for generic co-occurring allergy symptoms, not as a targeted MCAS treatment protocol.

Evidence for H1-antihistamines in primary MCAS is thin and dated (1983-1993 trials, moderate-to-high risk of bias); concludes there isn't good comparative evidence for any single agent. General-MCAS evidence, not ME/CFS-specific.

Recommends stepwise approach (H1 antihistamines first-line, H2 added empirically, then cromolyn/ketotifen/omalizumab for refractory cases) but states plainly the evidence base is very limited, relying primarily on expert opinion and mechanistic extrapolation.

Quercetin phytosome 500mg/day for 2 months significantly improved fatigue, sleep quality, step count, and physical performance vs placebo - mechanistically plausible via mast-cell-stabilizing action, but trial did not select for or measure MCAS/ME/CFS status.

Fexofenadine + famotidine for 20 days resolved fatigue in 43%, brain fog in 43%, tachycardia in 57% of treated Long COVID patients selected for MCA-attributed symptoms, vs untreated controls; 29% achieved complete resolution.

Summarizes real-world ME/CFS clinical practice: combined H1+H2 antihistamines first step, cromolyn as stabilizer (~15% get severe diarrhea), ketotifen as alternative, quercetin as OTC option. Cites Bateman Horne Center clinicians but is patient-journalism, not peer-reviewed.

Rated immunomodulatory drug evidence (rituximab, IVIG, rintatolimod) as mostly low/very-low quality; rituximab showed no benefit on fatigue/function with moderate-to-high-quality evidence of harm. Concluded these drugs should not be used to treat or cure ME/CFS.

States there is no cure or FDA-approved treatment; a commissioned systematic evidence review found insufficient evidence to support formal clinical management guidelines. Does not endorse rituximab or IVIG.

Found generally sparse, low-quality, inconsistent evidence across ME/CFS pharmacological interventions. Predates the definitive 2019 rituximab RCT so its conclusions on that specific drug are now outdated.

Major/moderate response in 10/15 (67%) rituximab-treated patients vs 2/15 (13%) placebo (p=0.003) - a striking early signal, with delayed response (months after infusion). This is the finding that drove years of follow-on excitement.

Clinically significant response in 18/28 (64%) patients over 15 months of maintenance infusions - reinforced optimism but, lacking blinding/control, could not establish causality. Directly motivated the definitive phase III trial.

THE definitive trial: response rate 26.0% rituximab vs 35.1% placebo - numerically LOWER in the treatment arm, not statistically significant (p=0.22). No difference in fatigue, function, activity, or QoL measures; more adverse events with rituximab. Decisively failed to replicate the earlier pilot/open-label results.

Significant mean functional improvement (school attendance, activity, social engagement) at 6-month follow-up vs placebo - one of the few positive IVIG trials in this literature, though small and pediatric-specific.

10/23 (43%) IVIG patients showed substantial symptom reduction vs 3/26 (13%) placebo (p<0.01) - but not confirmed in this same group's own larger follow-up trial, a smaller echo of the rituximab pattern.

Accurately and even-handedly summarizes the RituxME phase III negative result; reports the charity cancelled a planned follow-on study due to insufficient treatment responders to analyze - a sober account that doesn't oversell the earlier pilot data.

States no dietary, vitamin, or supplement interventions were recommended due to insufficient evidence; recommends only a well-balanced diet, adequate fluids, and dietetic referral for malnutrition risk. Does not endorse elimination, low-histamine, or gluten-free diets.

States a well-balanced diet is important but does not endorse any specific restrictive/elimination diet; cautions that many treatments marketed as cures are unproven, costly, and potentially dangerous.

Across studies from 1994-2016, only narrow inconsistent positive signals emerged (D-ribose, omega-3, one of three polynutrient studies); overall evidence for dietary modification was narrow and inconsistent.

Insufficient evidence for nutritional supplements AND elimination or modified diets to relieve symptoms - the review most directly on point for elimination/modified diets specifically.

Low-sugar/low-yeast elimination-style diet showed no statistically significant difference in fatigue or quality of life versus standard healthy-eating advice - the restrictive diet conferred no added benefit.

Significantly improved Mediterranean diet adherence and nutrient quality at 3/6/12 months - but measured diet adherence, not fatigue/symptom outcomes, which the authors flag as still needing evaluation.

Explicitly discourages restrictive/elimination diets (gluten-free, dairy-free) in the absence of scientific evidence of benefit; recommends gluten-free only after coeliac ruled out, warns of malnutrition risk especially in severe ME/CFS.

Offers practical PEM/crash-management nutrition guidance rather than endorsing any named elimination or anti-inflammatory diet; advises consulting a clinician before drastic diet changes.

States no drugs are licensed for ME/CFS and does not endorse any emerging candidate (metformin, BC007, aripiprazole, AXA1125, stellate ganglion block); recommends only symptomatic pharmacological management.

States there is no approved treatment; describes surveillance and clinical studies but does not name or endorse any specific emerging pharmacological candidate.

Low-dose aripiprazole (0.2-2.0mg/day, off-label) associated with statistically significant improvement in fatigue, brain fog, unrefreshing sleep among ~74% of responders; no RCT conducted yet.

A single acute infusion of CT38 (CRFR2 agonist) produced sustained (28+ day) improvement in composite symptom score at optimal dose (-25.7%, p=0.009); no larger controlled follow-up published since.

Sequential bilateral stellate ganglion blocks improved cognition, physical/social functioning, and POTS symptoms; sleep and cortisol did not improve. A follow-on RCT (STAR-CO) is now underway, though Long-COVID-focused rather than ME/CFS-specific.

Long-COVID-specific, not ME/CFS. Significantly neutralized GPCR autoantibodies and improved fatigue scales vs placebo, but the trial sponsor announced the study overall did not meet its bar for success. No confirmed Phase III in ME/CFS to date.

Long-COVID-specific, not ME/CFS. Significantly improved patient-reported fatigue vs placebo but did NOT hit its primary mitochondrial-imaging endpoint. Sponsor Axcella subsequently wound down clinical operations.

Explicitly notes NO completed or actively-enrolling metformin trial exists in ME/CFS specifically; rationale draws on a large Long COVID prevention RCT (~1125 participants, ~40% incidence reduction) plus a 6-patient fibromyalgia pilot as reasons to trial it.

Reviews the broader ME/CFS trial pipeline; discusses CT38 as promising but experimental, mentions BC007 as promising based on Long COVID case reports rather than ME/CFS RCT data.

Confirms metformin has significant Long-COVID RCT evidence but is still not being trialed in fibromyalgia or ME/CFS as of publication - corroborates the evidence gap identified in the Fineberg 2025 review.

Advocacy-org framing of the stellate ganglion block pilot study, noting Solve M.E.'s funding role and the case for larger trials.

Specific tapering protocol circulating: 3.5mg patch x3 days, 7-7.5mg x4 days, back to 3.5mg x3 days, stop. Theorized alpha-7 nicotinic receptor mechanism, same anti-inflammatory vagal pathway as Mestinon/tVNS.

0.1-2mg/day dosing; ME/CFS retrospective found 74% improved in at least one domain, long-COVID retrospective found only 22% clinically meaningful improvement (12% worse). Patient community independently and consistently reports an initial-response-fades-after-weeks-to-months ('poop-out') pattern across multiple independent threads.

89% of refractory MCAS patients reported clinical benefit across inflammatory/allergic/neurologic/GI/autonomic domains after GLP-1/GIP agonist therapy (tirzepatide-class drugs), independent of weight loss. Single-center, no control group.

OP (~80% improvement) + 15+ independent commenters report benefit from very-low-dose tirzepatide (0.1-0.75mg, well below standard 2.5mg+ diabetes/weight-loss dosing) for brain fog/energy/PEM severity; ~8 independent commenters report worsening or no effect (dysautonomia, GI shutdown, depression, hair loss, disturbed sleep) - genuinely mixed, not one-sided. A real, ongoing Scripps RCT (LoCITT-T, NCT07128082, ~1000 participants) is testing this directly, results ~14 months after recruitment closes.

High prevalence of hypermobility, craniocervical obstruction, and signs of intracranial hypertension in a large ME/CFS cohort; first study of ME/CFS focused on mechanical pathophysiology at this scale.

CSF opening pressure relates to craniocervical anatomy and symptom severity in ME/CFS.

Illustrates real diagnostic overlap/confounding risk between cervical spinal stenosis and ME/CFS — relevant to differential diagnosis, not just causal theory.

Cervical decompression/fusion surgery associated with marked improvement in ME/CFS symptoms in a handful of patients with confirmed cervical spinal stenosis.

Sustained, active discussion of cervical collar, prolotherapy, PICL stem-cell injection (~$10k), and craniocervical fusion surgery for suspected CCI. Named surgeons discussed: Bolognese (NY), Gilete (Spain), Henderson. One thread explicitly warns of 'improvement, decline, and even death' from fusion pursued on this theory, referencing the Jeff Wood case.

Establishes the fibrinaloid microclot mechanism (SARS-CoV-2 spike protein misfolds fibrinogen) and proposes triple anticoagulant therapy. Foundational paper for this hypothesis, published in Biochem J 479:537-559.

Genuinely split signal: some patients report meaningful benefit ('preventing PEM'), roughly equal numbers report zero effect after $300-1400 spent, and a real subset report the therapy itself triggering PEM/crashes at even low doses.

Childhood trauma history associated with ~6x increased risk of later CFS, dose-response relationship (more trauma types/severity = higher risk); sexual/emotional abuse and emotional neglect were the strongest discriminators. Trauma history also predicted a distinct hypocortisolism pattern, linking to the HPA axis mechanism already tracked separately.

History of PTSD associated with >8x increased odds of CFS, holding after controlling for shared genetics/environment via within-twin-pair analysis - a stronger design than most case-control studies in this field.

Self-selected sample (OP invited abuse-history stories) but ~25+ commenters independently describe childhood abuse/neglect preceding ME/CFS onset. Real signal is the theme's unprompted recurrence in the separate, general 'how did it start' thread (S275). One commenter (OwlOdyssey) named the 'trauma + viral infection' combined-mechanism theory explicitly, consistent with existing Post-viral onset and HPA axis categories.

Past-year concussion reported at 15.9% in people with ME/CFS vs 3.0% in those without - a striking, underexplored association warranting a dedicated literature pass.

Open, unprompted ~90-commenter thread - highest-value convergence data in the sweep. Largest cluster (45+) is viral/infectious onset, reaffirming the existing Post-viral category. Second cluster (~9) is non-infectious physical trauma (TBI, surgery, hysterectomy, sepsis, animal attack, chemo). Also: tick-borne illness/PTLDS (S267), vaccine-associated onset (S261), severe psychological stress without documented infection (~8 mentions, maps to HPA axis not the Ruled-Out psychiatric-cause category), hypermobility/EDS as general comorbidity (~7 mentions), genetic/family clustering (corroborates existing Genetic predisposition category).

Genuine peer-reviewed case reports exist connecting ME/CFS-like onset to vaccination (BNT162b2, third COVID dose, Gam-COVID-Vac/Sputnik V), plus an emerging 'post-acute COVID-19 vaccination syndrome' research thread. No controlled/comparative study establishes causality - case-report/self-referred-cohort tier only.

Global DTI-ALPS index (diffusion-MRI proxy for glymphatic/perivascular clearance) lower in ME/CFS (1.44 vs 1.51, p=0.014), correlated with sleep-disturbance severity (r=-0.47) and impaired concentration (r=-0.43). First application of this measure to ME/CFS. Small pilot, contested proxy measure, no longitudinal component; widely oversold on social media as 'the underlying cause' when the paper itself is hedged.

OP headline oversells the Thapaliya et al. 2026 glymphatic study (S257) as 'the underlying cause.' Top comments (tamerarehen, HauntedByOddParsnip, raccoonwillnotforget) correctly pushed back with accurate small-N/indirect-measure critique. One legitimate corroborating tangent: a mouse migraine study showing impaired glymphatic clearance produces migraine-like symptoms in a non-deconditioned population.

Same underlying study as S268 (S257), but headline framing on r/science was considerably more measured. Top comment (NotAFishEnt) quoted the actual abstract verbatim including hedged conclusion language; other comments (manslvl2, Nalena_Linova) independently corroborated that DTI-ALPS validity as a glymphatic proxy is disputed within the imaging field.

Urinary mycotoxins detected in 93% of a CFS patient cohort tested, and water-damaged-building exposure history in >90% of the same cohort. Empirical basis for the broader CIRS (Chronic Inflammatory Response Syndrome, Ritchie Shoemaker) framework.

Pain Reprocessing Therapy produced 66% pain-free at 4 weeks in chronic back pain, with matching brain-imaging changes. This is real RCT support for the reprocessing mechanism itself, but in chronic back pain, not ME/CFS - no CFS-specific RCT of the Sarno/Schubiner/JournalSpeak model was found.

OP (24F, post-mono/post-COVID) attributes full recovery to JournalSpeak/PRT/TMS model after ~2 years. Most-corroborated recovery claim across this entire Reddit sweep: 12+ independent commenters report meaningful improvement or full recovery via the same or closely related methods. Also drew the strongest pushback of any claim in the sweep (multiple 13+ year patients report zero effect; several call the causal framework unsupported by biological evidence).

40 daily HBOT sessions produced significant improvement in cognition, energy, sleep, and pain vs. sham in long COVID patients.

Only 10 HBOT sessions produced no significant difference vs. sham on either primary outcome (Physical Functioning or Role-Physical) at 13 weeks. A non-pre-specified exploratory analysis at 52 weeks did favor HBOT (65.8% vs 40.6% achieving clinically meaningful improvement, p=0.033), but this is post-hoc, not the trial's primary result.

40 HBOT sessions produced significant improvement in physical function (SF-36) and MRI evidence of thalamic hyperconnectivity normalizing in treatment responders - a genuinely novel biological correlate. Diagnosed ME/CFS population (unlike most of the drug-trial literature, which is long-COVID-only), but uncontrolled/single-center; authors call for controlled follow-up.

OP describes hard-chamber HBOT (1hr sessions, 2x/week, ~16 sessions before effect). Comments describe a range of hard-chamber HBOT protocols (35-42+ sessions) with reported benefit, consistent with the session-count-dependent pattern seen in the controlled trial literature (S280, S281).

Distinguishes three separate modalities patients often conflate: plain supplemental oxygen at rest/post-exertion (no published evidence, untested extrapolation), mHBOT/mild hyperbaric (commercial wellness chains, below the 1.5-2 ATA threshold the clinical literature actually studied - a real evidence-mismatch risk), and hard-chamber HBOT (the modality with actual RCT evidence, S280-S282). IHHT also mentioned as a distinct, separately-emerging modality with its own nascent trial pipeline (Doehner 2024 long-COVID pilot; NCT07317401 ME/CFS-specific trial now recruiting) - not to be conflated with HBOT.